How long does a GLP-1 drug stay in your system after you stop?

Semaglutide has an elimination half-life of about one week, so it takes roughly five to seven weeks to clear from your body after the last dose. Tirzepatide has a half-life of about five days and clears in roughly one month. Appetite suppression fades gradually over this period, not overnight.

Will I regain all the weight if I stop taking a GLP-1 drug?

Not necessarily, but most people regain a large share. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within one year of stopping semaglutide. In SURMOUNT-4, people who stopped tirzepatide regained 14% of body weight over the next year, while those who continued lost 5.5% more. Real-world data is more encouraging: in an Epic Research analysis of over 20,000 patients, 56% maintained or continued their weight loss a year after stopping semaglutide.

Do blood pressure and blood sugar go back up after stopping?

In the STEP 1 extension, most cardiometabolic improvements, including blood pressure, blood sugar, and lipid changes, reverted toward baseline within a year of stopping semaglutide. People with type 2 diabetes can expect blood sugar to rise after discontinuation, which is why stopping should always be planned with a doctor.

Is it dangerous to stop a GLP-1 drug suddenly?

GLP-1 drugs do not cause a withdrawal syndrome the way some medications do. The main effects of stopping are the return of appetite, gradual weight regain, and loss of blood sugar control in people with diabetes. Talk with your prescriber before stopping so you can plan for these changes, especially if you take the drug for type 2 diabetes or cardiovascular risk reduction.

What Happens When You Stop Taking a GLP-1 Drug?

The short answer: when you stop a GLP-1 drug, your appetite returns over several weeks, and most people regain a large share of the weight they lost. In the best clinical trial data, people regained about two-thirds of their lost weight within one year of stopping semaglutide. Blood pressure, blood sugar, and cholesterol improvements also drifted back toward where they started. Real-world results are less bleak, and some people do keep the weight off. But the research is clear that these drugs treat a chronic condition, and their effects do not persist on their own.

This is one of the most common questions people ask before starting a GLP-1 drug, and one of the most important. Here is what the trials actually measured.

How Fast Does the Drug Leave Your Body?

These are long-acting drugs, so nothing changes on day one. Semaglutide (Ozempic, Wegovy) has an elimination half-life of about one week, according to the FDA label for Wegovy. That means it takes roughly five to seven weeks after your last injection for the drug to fully clear. Tirzepatide (Mounjaro, Zepbound) has a half-life of about five days, per the Zepbound label, so it clears in about a month.

In practice, people notice appetite creeping back over the first few weeks. Food noise, the constant background pull toward eating that these drugs famously quiet, tends to return as drug levels fall. Side effects like nausea fade over the same period.

How Much Weight Comes Back?

Two rigorous trials answer this directly, one for semaglutide and one for tirzepatide.

Semaglutide: the STEP 1 extension

In the STEP 1 trial, participants lost an average of 17.3% of body weight over 68 weeks on semaglutide 2.4 mg. Then treatment stopped, and researchers followed 327 participants for another year off the drug. By week 120, they had regained an average of 11.6 percentage points of that lost weight. That is about two-thirds of the loss given back. Their net result was 5.6% below starting weight, down from 17.3% (Wilding et al., Diabetes, Obesity and Metabolism 2022).

Tirzepatide: SURMOUNT-4

SURMOUNT-4 was built to test exactly this question. All 670 participants took tirzepatide for 36 weeks and lost an average of 20.9% of body weight. Then half were switched, blinded, to placebo. Over the next year, the placebo group regained 14.0% of body weight while the group that stayed on tirzepatide lost an additional 5.5%. At week 88, the continued-treatment group was down 25.3% from baseline; the group that stopped was down only 9.9%. Just 16.6% of those who stopped kept at least 80% of their initial loss, compared with 89.5% of those who continued (Aronne et al., JAMA 2024).

The pattern in both trials is the same. Regain starts within weeks of stopping, is steepest in the first several months, and continues through the first year.

Do the Other Health Benefits Reverse?

Mostly, yes. In the STEP 1 extension, the improvements in blood pressure, blood sugar, C-reactive protein, and lipids that came with weight loss reverted toward baseline over the year off the drug (Wilding et al., 2022). A post hoc analysis of SURMOUNT-4 found the same thing with tirzepatide: as weight returned, so did the cardiometabolic risk factors.

Two groups need to plan especially carefully before stopping:

People with type 2 diabetes. GLP-1 drugs actively lower blood sugar. Stop the drug and A1C rises, which may require a change in your other diabetes medications.
People taking semaglutide for heart protection. The SELECT trial showed a 20% reduction in major cardiovascular events with ongoing treatment. Like a statin, the protection is a benefit of continued use, not a permanent fix. We cover that evidence in depth in our article on GLP-1 drugs and heart health.

Does Everyone Regain the Weight?

No, and this is where real-world data diverges from the trials in an encouraging way. An Epic Research analysis of electronic health records looked at 20,274 patients who stopped semaglutide. One year later, 56.2% had maintained their weight or kept losing, while 17.7% had regained everything or more. Results for liraglutide were nearly identical.

Why the gap between trials and the real world? Trial participants stop abruptly and completely, on a schedule the protocol sets. Real patients stop for many reasons, at many different doses, and some ramp up diet and exercise efforts precisely because they know the drug is going away. Averages also hide wide individual variation: in every study, some people regain quickly, and some hold steady for a long time.

Why Does the Weight Come Back?

Because the biology the drug was suppressing is still there. Obesity research has shown for decades that the body defends its weight. After weight loss, hunger hormones like ghrelin rise, satiety signals fall, and energy expenditure drops. GLP-1 drugs counter those pressures directly by acting on appetite circuits in the brain and slowing stomach emptying. Remove the drug and the old signals come back, usually with the same strength as before.

This is why obesity specialists increasingly describe GLP-1 treatment the way they describe blood pressure treatment. The medication controls the condition while you take it. It does not cure the condition. Regain after stopping is not a personal failure, and it is not evidence the drug "didn't work." It is the expected course of a chronic disease when treatment stops.

What Helps You Keep the Weight Off?

If you and your doctor decide to stop, the evidence points to a few things that improve your odds:

Resistance training and protein. Preserving muscle during and after treatment protects your metabolic rate. Our guide to exercise on GLP-1 medications covers why this matters more than most people expect.
A structured plan, not an abrupt cliff. Keep food logging, regular weigh-ins, or dietitian support in place through the high-risk first six months. In the Epic data, people who stopped after longer, more complete treatment courses did better than early quitters.
A plan to restart if needed. Many clinicians set a weight threshold with patients in advance. If regain crosses it, treatment resumes. Cost is often the real reason people stop, so it is worth reading our breakdown of GLP-1 cost and insurance options before making a purely financial decision.
Medical supervision, always. Especially with diabetes, never stop without talking to your prescriber first.

The Bottom Line

Stopping a GLP-1 drug reverses most of its effects over about a year. The best trial data shows roughly two-thirds of lost weight returning after semaglutide, and a 14% body-weight regain in the year after stopping tirzepatide, along with the return of blood pressure, blood sugar, and cholesterol toward pre-treatment levels. Real-world records are more hopeful, with over half of patients holding their weight a year out. If you take semaglutide specifically, our sister site ozempic.md covers drug-specific dosing schedules and discontinuation questions in more detail.

The practical takeaway: think of a GLP-1 drug as a long-term treatment, plan the exit with your doctor if you need one, and build the muscle, habits, and support that give you the best chance of keeping what you gained. Or rather, what you lost.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider about treatment decisions.